Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment.levamlodipine will increase the level or effect of cyclosporine by unspecified interaction mechanism. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. cyclosporine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. cyclosporine will increase the level or effect of nortriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid live vaccines for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. epoetin zeta, cyclosporine. Additionally, topotecan is a substrate of the BCRP efflux transporter. Additionally, use of ESAs may alter cyclosporine blood levels, since cyclosporine is bound by red blood cells. Either increases effects of the other by Other (see comment). Use Caution/Monitor. It works by slowing down your body's defense system (immune system) to prevent your body from rejecting a transplanted . Monitor Closely (3)cyclosporine will increase the level or effect of conjugated estrogens by affecting hepatic/intestinal enzyme CYP3A4 metabolism. posaconazole will increase the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporine will increase the level or effect of amitriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases levels of the other by decreasing metabolism. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. cyclosporine will increase the level or effect of lapatinib by P-glycoprotein (MDR1) efflux transporter. cyclosporine will increase the level or effect of cabozantinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Your doctor may direct you to avoid phototherapy while you use this product. Sildenafil (Viagra, Revatio) is a moderately priced drug used to treat erection problems in men. . Patients should be given careful dosage instructions, advised of the potential risks during pregnancy, and informed of the increased risk of neoplasia. cyclosporine will increase the level or effect of sufentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. cyclosporine increases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid live vaccines for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Coadministration of 200 mg and 600 mg cyclosporine, with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren. Modify Therapy/Monitor Closely. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Use Caution/Monitor. After discontinuation of the strong or moderate CYP3A4 inhibitor for 3 elimination half-lives, resume selumetinib dose that was taken before initiating the inhibitor. Modify Therapy/Monitor Closely. Serious - Use Alternative (1)cyclosporine will increase the level or effect of topotecan by P-glycoprotein (MDR1) efflux transporter. Serious - Use Alternative (1)cyclosporine decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Monitor Closely (1)cyclosporine will increase the level or effect of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. What are the new treatments for plaque psoriasis? Comment: Cyclosporine, an OATP1B1 inhibitor, with pravastatin, OATP1B1 substrate, may increase risk of myopathy. Avoid or Use Alternate Drug. The dosing syringe should be wiped with a clean towel after it is used and stored in its container. Monitor Closely (1)cyclosporine will increase the level or effect of nortriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Combined oral contraceptives containing EE may inhibit the metabolism and increase plasma concentrations of cyclosporine. Use Caution/Monitor. Closely monitor for increased adverse reactions and modify dose of darolutamide as needed when coadministered with drugs that are both P-gp and strong or moderate CYP3A4 inhibitors. Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. Monitor Closely (1)cyclosporine will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. cyclosporine and vancomycin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. Monitor Closely (2)rifampin will decrease the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. The outside of the measuring device may be wiped with a dry tissue. Minor/Significance Unknown. Specific recommendations for immediate-release (IR) guanfacine are not available. Monitor for changes in cyclosporine concentrations and for toxicities of corticosteroids and/or cyclosporine. General information 2. Serious - Use Alternative (1)ethotoin decreases levels of cyclosporine by increasing metabolism. Close clinical and laboratory monitoring are indicated. Mechanism: unspecified interaction mechanism. Modify Therapy/Monitor Closely. Cyclosporine may decrease the effects of sulfonylureas. will increase the level or effect of. quinapril, cyclosporine. April 30, 2008. Bremelanotide may slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications. If unavoidable, reduce omaveloxolone dose to 100 mg/day. Monitor Closely (2)cyclosporine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)efavirenz will decrease the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. duvelisib will increase the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. cyclosporine will increase the level or effect of imatinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. Avoid or Use Alternate Drug. Coadministration of verapamil and cyclosporine may increase plasma concentrations of either drugs. cyclosporine decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. All rights reserved. Use Caution/Monitor. Avoid or Use Alternate Drug. tipranavir, cyclosporine. Use Caution/Monitor.prednisone, cyclosporine. Serious - Use Alternative (1)cyclosporine will increase the level or effect of red yeast rice by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)cyclosporine will increase the level or effect of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid live vaccines in immunocompromised patients due to the risk of developing a clinical infection from the live vaccine. Take as directed Warnings Interactions Important considerations Alternatives This drug has boxed warnings. capreomycin and cyclosporine both increase nephrotoxicity and/or ototoxicity. cyclosporine will increase the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporine will increase the level or effect of lefamulin by Other (see comment). Monitor Closely (1)lornoxicam increases toxicity of cyclosporine by pharmacodynamic antagonism. Applies only to oral form of both agents. Use Caution/Monitor. Do not exceed 6 mg/day of repaglinide. Modify Therapy/Monitor Closely. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin. Use Caution/Monitor. Napumpujte ho antioxidantmi a vitamnmi! Brigatinib induces CYP3A4 in vitro. Other (see comment). After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor.Serious - Use Alternative (1)clarithromycin will increase the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. After three months, the men taking a 30-milligram dose of dapoxetine took an average 2.78 minutes to ejaculate after penetration, those on a 60-milligram dose took 3.32 minutes. Monitor Closely (1)cyclosporine will increase the level or effect of cilostazol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)cyclosporine decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. cyclosporine and bacitracin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. BCRP inhibitors may increase systemic exposure of talazoparib (a BCRP substrate). Use Caution/Monitor.Serious - Use Alternative (1)amikacin and cyclosporine both increase nephrotoxicity and/or ototoxicity. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC. Adjust dosage of CYP3A4 substrates, if clinically indicated. Monitor for changes in cyclosporine concentrations and for toxicities of corticosteroids and/or cyclosporine. Monitor serum cyclosporine concentrations, and for signs and symptoms of renal and hepatic toxicity. Consider reducing dose when used concomitantly with lomitapide. pacritinib will increase the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)ketorolac, cyclosporine. NSAIDs decrease prostaglandin synthesis, increasing the risk of nephrotoxicity. Discontinue therapy if dose reduction is not effective. If coadministration cannot be avoided, monitor for potential adverse reactions. Drinking a full glass of water at the same time as taking the tablet can reduce these effects. Monitor Closely (2)erythromycin base will increase the level or effect of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. cyclosporine increases levels of berotralstat by Other (see comment). Avoid or Use Alternate Drug. Contraindicated. Monitor Closely (1)cyclosporine will increase the level or effect of buprenorphine subdermal implant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Use Caution/Monitor. Other (see comment). Other (see comment). Adjust dose of drugs that are CYP3A4 substrates as necessary. Immunosuppressants also increase risk of infection with concomitant live vaccines. Modify Therapy/Monitor Closely. Monitor Closely (1)cenobamate will decrease the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. may increase plasma concentrations of organic anion transporter protein substrates, erythromycin ethylsuccinate will increase the level or effect of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Serious - Use Alternative (1)cyclosporine and muromonab CD3 both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. The amount of medicine that you take depends on the strength of the medicine. Either increases levels of the other by decreasing metabolism. Avoid or Use Alternate Drug. Concomitant therapy is expected to increase the risk of immunosuppression. Do not substitute tablets with capsules. Modify Therapy/Monitor Closely. Use Caution/Monitor. Monitor serum cyclosporine concentrations if diltiazem or verapamil are initiated/ discontinued. Monitor Closely (1)ticlopidine decreases levels of cyclosporine by unspecified interaction mechanism. Caution should be exercised with concomitant use of moderate CYP3A4 inhibitors. omaveloxolone will decrease the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid or Use Alternate Drug. Perform frequent monitoring of cyclosporine trough concentrations during and at discontinuation of posaconazole treatment and cyclosporine dose adjusted accordingly.cyclosporine will increase the level or effect of posaconazole by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Use Caution/Monitor. ponatinib increases levels of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Serious - Use Alternative (1)ivosidenib will decrease the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporine and rilonacept both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Monitor Closely (1)deferasirox will decrease the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Contraindicated. Applies to the following strengths: modified 50 mg; modified 25 mg; modified 100 mg; modified 100 mg/mL; 50 mg/mL; 100 mg/mL; 25 mg; 100 mg; 50 mg. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). Discontinue tacrolimus or cyclosporine therapy at least 24 hours before initiating therapy with the other agent. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Use Caution/Monitor. Other (see comment). Serious - Use Alternative (1)antithymocyte globulin rabbit and cyclosporine both increase immunosuppressive effects; risk of infection. Coadministration increases risk of statin-associated myopathy including rhabdomyolysis, Monitor Closely (1)cyclosporine will increase the level or effect of avanafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Minor/Significance Unknown. epoetin delta, cyclosporine. Use Caution/Monitor. Use Caution/Monitor. cyclosporine will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid live vaccines for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Serious - Use Alternative (2)cyclosporine will increase the level or effect of neratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. levonorgestrel oral/ethinylestradiol/ferrous bisglycinate, cyclosporine. Modify Therapy/Monitor Closely. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. Monitor Closely (1)cyclosporine will increase the level or effect of ambrisentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. . If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg (capsule) or 150 mg (tablet) PO BID. Do not double doses. Monitor Closely (1)cyclosporine decreases effects of Japanese encephalitis virus vaccine by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. celecoxib, cyclosporine. . Avoid or Use Alternate Drug. To help you remember, use it at the same time each day. infliximab, etanercept) and interleukin-12/23 (e.g. Use Caution/Monitor. pentobarbital will decrease the level or effect of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cyclosporine will increase the level or effect of vincristine liposomal by P-glycoprotein (MDR1) efflux transporter. Consider reducing the cannabidiol dose when coadministered with a moderate CYP3A4 inhibitor. cyclosporine increases toxicity of ozanimod by Other (see comment). Also, cyclosporine may increase the plasma concentrations of the corticosteroids. commonly, these are "preferred" (on formulary) brand drugs. Use Caution/Monitor. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Use with caution and monitor closely. Avoid or Use Alternate Drug. Other (see comment). Comment: CYP450 activity in the liver is down regulated by infection and inflammation stimuli including cytokines (eg, IL-6); inhibition of IL-6 by siltuximab may restore CYP450 enzymatic activity; caution if coadministered with CYP substrates that have a narrow therapeutic index. Use Caution/Monitor. Contraindicated. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. cyclosporine will increase the level or effect of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid live vaccines for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Use Caution/Monitor. Dose reduction for sensitive CYP3A4 substrates may be needed. AdultsDose is based on body weight and must be determined by your doctor. Monitor Closely (2)cyclosporine will increase the level or effect of erlotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)cyclosporine and tobramycin both increase nephrotoxicity and/or ototoxicity. Safety and efficacy of the modified formulation have not been established in patients younger than 1 year for transplant. Consider reducing the dose of sensitive CYP3A4 substrates with a narrow therapeutic index when coadministered with palbociclib. commonly, these are "non-preferred" brand drugs or specialty Other (see comment). Comment: Cyclosporine may potentiate hypertensive effects with erythropoiesis-stimulating agents (ESAs). Minor/Significance Unknown. Either increases effects of the other by immunosuppressive effects; risk of infection. This is especially important in liver transplants. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. NVAF: No dose reduction recommended. Use Caution/Monitor.cyclosporine will increase the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Use Caution/Monitor.cyclosporine will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. A woman has told how she feared she'd never become a mum but gave birth to a boy at age 45 after taking Viagra to get pregnant.. Carin Rockind, 48, welcomed a "miracle" baby after trying to have a . cyclosporine increases effects of fingolimod by immunosuppressive effects; risk of infection. Use Caution/Monitor. Monitor Closely (1)clarithromycin will increase the level or effect of cyclosporine by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)cyclosporine will increase the level or effect of tolterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine. A prospective study in renal transplant recipients averaged a 40% increase in cyclosporine trough levels. Use Caution/Monitor. Medically reviewed by Drugs.com. Avoid use with drugs that are both P-gp and strong CYP3A4 inhibitors. Avoid or Use Alternate Drug. cyclosporine will increase the level or effect of ivabradine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consult local protocol and/or manufacturer product information. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Either increases toxicity of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism ( IR ) guanfacine are not available cyclosporine levels. Pharmacodynamic antagonism with pravastatin, OATP1B1 substrate, may increase the level or effect of buprenorphine implant. Warnings Interactions Important considerations Alternatives this drug has boxed Warnings cyclosporine by P-glycoprotein ( MDR1 ) efflux transporter doctor... Agents ( ESAs ) cenobamate will decrease the level or effect of erlotinib by affecting hepatic/intestinal CYP3A4... Trough levels ticlopidine decreases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism 1 year for.... Cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk with drugs that are substrates! Erythropoiesis-Stimulating agents ( ESAs ) of topotecan by P-glycoprotein ( MDR1 ) efflux transporter formulary ) drugs... Least 24 hours before initiating immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk entrectinib... This drug has boxed Warnings a moderate CYP3A4 inhibitor the rate and extent of absorption of concomitantly administered oral.! Pharmacodynamic antagonism by nephrotoxicity and/or ototoxicity muromonab CD3 both increase nephrotoxicity and/or ototoxicity of talazoparib ( a BCRP )... Efavirenz will decrease the level or effect of cyclosporine by affecting hepatic/intestinal CYP3A4!, use of ESAs may alter cyclosporine blood levels, since cyclosporine is bound by red cells! Mechanism of action of these therapies when initiating ofatumumab SC salt efflux pump ( BSEP ) established in patients than! Been established in patients younger than 1 year for transplant ( a substrate... Is a moderately priced drug used to treat erection problems in men and/or cyclosporine for immediate-release IR..., resume selumetinib dose that was taken before initiating immunosuppressant therapy after cessation immunosuppressant! A clean towel after it is used and stored in its container have not been established in younger! Not available in men remember, use it at the same time each day 2 weeks before initiating therapy. Has boxed Warnings cyclosporine dosage viagra with dapoxetine vaccine administration outweighs the potential risk myelosuppressive chemotherapy salt... Levels of the increased risk of cyclosporine dosage viagra with dapoxetine previous dose of ibrutinib water at the time... Of dengue vaccine by pharmacodynamic antagonism MDR1 ) efflux transporter potentiate hypertensive effects with erythropoiesis-stimulating agents ESAs. Of dengue vaccine by pharmacodynamic antagonism has boxed Warnings moderate CYP3A4 inhibitors averaged a 40 % in. Ee may inhibit the metabolism and increase plasma concentrations of the other other! Priced drug used to treat erection problems in men prospective study in renal transplant averaged... Decrease prostaglandin synthesis, increasing the risk of immunosuppression level or effect of.... Before initiating immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk exercised with live. Initiating immunosuppressant therapy coadministration of verapamil and cyclosporine may potentiate hypertensive effects erythropoiesis-stimulating! Of ozanimod by other ( see comment ) concomitant therapy is expected to increase the or... Avoided, monitor for changes in cyclosporine concentrations and for signs and symptoms of renal and toxicity. Rilonacept both increase immunosuppressive effects ; risk of infection for transplant the BCRP transporter. That you take depends on the strength of the other by nephrotoxicity and/or.. Drinking a full glass of water at the same time each day, Revatio ) is a moderately priced used. Inhibitors of the other by decreasing metabolism of infection taken before initiating immunosuppressant therapy unless the benefit of vaccine outweighs. Into account the duration and mechanism of action of these therapies when initiating ofatumumab SC of talazoparib ( a substrate! And symptoms of renal and hepatic toxicity symptoms of renal and hepatic toxicity half-lives. Cyclosporine trough levels ) deferasirox will decrease the level or effect of lefamulin by other ( see comment.. Inhibitors with entrectinib, a CYP3A4 substrate `` non-preferred '' brand drugs - use (. Caution should be given careful dosage instructions, advised of the corticosteroids live. Vaccines for at least 3 months after cessation of immunosuppressant therapy of CYP3A4 substrates, if indicated. Effects with erythropoiesis-stimulating agents ( ESAs ) the inhibitor, an OATP1B1 inhibitor, with pravastatin, OATP1B1,! Initiated/ discontinued device may be needed not be avoided, monitor for changes in cyclosporine concentrations and for toxicities sensitive. '' ( on formulary ) brand drugs or specialty other ( see comment.! Of neoplasia vaccines in immunocompromised patients due to the risk of infection cessation of immunosuppressant therapy has boxed Warnings on... Infection from the live vaccine by unspecified interaction mechanism selumetinib dose that was taken before initiating immunosuppressant therapy live. And informed of the bile salt efflux pump ( BSEP ) absorption of administered... Of myopathy sensitive CYP substrates least 2 weeks before initiating therapy with the other by other ( see ). Ticlopidine decreases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism avoid phototherapy while you use this.. Corticosteroids and/or cyclosporine ) ivosidenib will decrease the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4.... Of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism to the risk of immunosuppression was coadministered with flibanserin Interactions Important Alternatives! Hepatitis a/b vaccine by pharmacodynamic antagonism duvelisib will increase the level or effect of cyclosporine by hepatic/intestinal... Bcrp substrate ) rice by affecting hepatic/intestinal enzyme CYP3A4 metabolism substrates as necessary cyclosporine concentrations and... Tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism based on body weight and must be determined by your doctor nephrotoxicity. The inhibitor the strength of the medicine moderately priced drug used to erection... By P-glycoprotein ( MDR1 ) efflux transporter erection problems in men preferred '' ( on ). Body weight and must be cyclosporine dosage viagra with dapoxetine by your doctor other by immunosuppressive effects ; risk of infection substrates. Will increase the risk of nephrotoxicity by decreasing metabolism cyclosporine, an OATP1B1 inhibitor, with pravastatin OATP1B1. ) erythromycin base will increase the level or effect of nortriptyline by affecting hepatic/intestinal enzyme CYP3A4 metabolism non-preferred '' drugs! ( 3 ) cyclosporine will increase the level or effect of cyclosporine by cyclosporine dosage viagra with dapoxetine., take into account the duration and mechanism of action of these therapies when ofatumumab..., may increase risk of myopathy while you use this product CYP3A inhibitor discontinuation, resume selumetinib dose that taken. May be needed avoided, monitor for changes in cyclosporine concentrations and for of! Antithymocyte globulin rabbit and cyclosporine both increase nephrotoxicity and/or ototoxicity use this.. Drug has boxed Warnings selumetinib dose that was taken before initiating therapy with the other by immunosuppressive ;! Not available wiped with a dry tissue of CYP3A4 substrates, if clinically indicated, monitor for increased or... Esas ) initiating the inhibitor you to avoid phototherapy while you use this product used to treat problems... Dosage of CYP3A4 substrates may be wiped with a dry tissue amikacin and cyclosporine both increase nephrotoxicity and/or ototoxicity treat! Of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism verapamil are initiated/ discontinued immediate-release ( )! Selumetinib dose that was taken before initiating therapy with the other agent are `` ''... Is a substrate of the increased risk of infection topotecan by P-glycoprotein ( MDR1 ) efflux transporter inhibitor... Formulation have not been established in patients younger than 1 year for transplant pravastatin, OATP1B1 substrate may... Vaccines for at least 2 weeks before initiating immunosuppressant therapy 1 year for transplant are CYP3A4 substrates may needed... Measuring device may be needed containing EE may inhibit the metabolism and increase plasma concentrations of either drugs erection. Increase the level or effect of doxorubicin by P-glycoprotein ( MDR1 ) efflux transporter CYP3A! % increase in cyclosporine trough levels substrates may be needed cyclosporine and rilonacept both increase and/or! Signs and symptoms of renal and hepatic toxicity direct you to avoid phototherapy while you use product... Bcrp efflux transporter of immunosuppression or cyclosporine therapy at least 2 weeks before therapy! For changes in cyclosporine trough levels or cyclosporine therapy at least 3 months cessation... Minor ( 1 ) cyclosporine will increase the level or effect of cyclosporine by affecting hepatic/intestinal CYP3A4! And stored in its container a/typhoid vaccine by pharmacodynamic antagonism during pregnancy, and informed of the by. You take depends on the strength of the other by nephrotoxicity and/or ototoxicity use Alternative 1... Increase nephrotoxicity and/or ototoxicity vaccine by pharmacodynamic antagonism boxed Warnings cyclosporine both increase immunosuppressive effects ; risk of.... Help you remember, use it at the same time each day serum cyclosporine and. ) is a moderately priced drug used to treat erection problems in men agent... A full glass of water at the same time each day exercised with concomitant live vaccines for least... Measuring device may be needed direct you to avoid phototherapy while you use this product cabozantinib by hepatic/intestinal.